Skip to content

The Effect of AposTherapy on Pain and Function in a Non Specific Low Back Pain

The Effect of AposTherapy on Pain and Function in a Non Specific Low Back Pain Population. A Randomized Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03167671
Acronym
AposBack
Enrollment
164
Registered
2017-05-30
Start date
2017-08-15
Completion date
2023-01-28
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Low Back Pain

Keywords

Oswestry, SF 36, Promis Pain and Function, Berg Balance

Brief summary

AposTherapy is a home based exercise program utilizing footwear that causes exercise with normal activity that may significantly improve function in patients with back pain since patients with back pain have altered mechanics of motion contributing or due to the presence of the conditions. Capitalizing on the reported excellent adherence and clinical benefit of ApostTherapy in patients with significant knee and back pain, we propose to evaluate this as a conservative treatment that may supplant/supplement traditional pain medications and physical therapy in an at-risk urban inner city population.

Detailed description

AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity that may significantly improve function in patients with back pain in general, and specifically Axial Low Back Pain (NSLBP). Capitalizing on the reported excellent adherence and clinical benefit of Apos Therapy in patients with significant back pain, we propose to evaluate this as a conservative treatment that may supplant/supplement traditional pain medications and physical therapy in NSLBP population. A possible potential use of AposTherapy® as a replacement for traditional physical therapy may yield a less costly, more effective therapy with better adherence. Problems with traditional therapy include poor patient adherence to both outpatient and home therapy programs, the added cost of travel (which may be more than $100 per session for ambulette or access-a-ride for eligible patients), and the lack of continuation in an ongoing exercise program\[6-8\], all of which can lead to relapse and need for retreatment. Additionally, access to physical therapy is limited for many patients since there are not enough available outpatient therapy services to meet the needs of all patients. Finding an alternative exercise program that will increase adherence, decrease total therapy visits, and improve patient's outcomes with decreased dependence on pain medications is a high priority from both patient care and cost management perspectives. AposTherapy® potentially overcomes many of these issues by improving/modifying abnormal biomechanics (therefore decreasing pain), and providing an independent home-based exercise program utilizing footwear that causes exercise with normal activity by promoting perturbation. This biomechanical approach may significantly reduce pain and improve function in patients with nonspecific low back pain (NSLBP). Capitalizing on the reported excellent adherence and clinical benefit of AposTherapy® in patients with significant NSLBP, we propose to evaluate the biomechanical exercise (wearing an appropriately calibrated shoe at home for a prescribed amount of time each day) as a conservative treatment that may supplement or supplant traditional pain medications, interventional pain procedures and physical therapy in an at-risk urban inner city population with NSLBP.

Interventions

AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity

OTHERTraditional Physical Therapy

Up to 20 sessions of traditional physical therapy

Sponsors

Apos Medical and Sports Technology Ltd.
CollaboratorINDUSTRY
Montefiore Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

The outcomes assessor is the only one masked in the study. They are independent of the randomization, trial coordination, and care providers.

Intervention model description

Single blinded (evaluator), single-center, randomized controlled trial. Interventional and Control group with option for Control group to Cross over.

Eligibility

Sex/Gender
ALL
Age
30 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* •Patients suffering from symptomatic axial lower back pain for at least 24 weeks. * Patients with VAS pain score of ≥3cm (measured at baseline). * Males and females between the ages of 30-85. * 17\<BMI\<40 * Ambulatory and active patients that can participate in a rehabilitation program that includes daily walking * Stable medicine regimen (no recent changes to their pain medication within a month) * Able to walk at least 50 meters and scored positive on the STEADI test (Supp. 1) * Able to understand, read and sign the informed consent form * English or Spanish speaking

Exclusion criteria

* •Patients suffering from active inflammatory joint disease. * Patients with diagnosis of neuromuscular disease. * Patients with more than 3 falls in the last 52 weeks, OR any balance related fall with an injury in the last 52 weeks. * Patients exhibiting a lack of physical or mental ability to perform or comply with the study procedure. * Patients with a history of pathological osteoporotic fracture * Patients with referred pain consistent with radicular etiology * Patients with generalized body pain (both upper and lower extremities). * No spine surgery within 24 weeks. * No image guided lumbar intervention in the past 8 weeks. * No major cardiovascular comorbidities (able to enroll in an active exercise program) * Patient started on lipid lowering medication in last 12 weeks * Any change in blood pressure medications * No recent physical therapy for the back. (within the last 12 weeks) * No active heart disease (ischemia or heart failure admissions within 24 weeks) and no active COPD (exacerbation within 24 weeks) * No active malignancies on ongoing treatment * Patient with neurological gait pattern. * Patient requiring assistive device during gait analysis.

Design outcomes

Primary

MeasureTime frameDescription
Function1 YearImprovement in back pain measured and assessed with the Oswestry Disability Index (ODI).

Secondary

MeasureTime frameDescription
Pain medication consumption1 yearmedication consumption
Quality of life survey1 yearQuality of life assessed with Short Form Health Survey questionnaire
Gait assessment1 yearobjective analysis of patients' gait assessed with a pressure mat to demonstrate stride length, velocity, and symmetry.
6-min walk test1 yearobjective assessment using maximum distance comfortably walked in 6 minutes on a 100 foot closed course
Dynamic balance1 yearMeasured by Berg balance test assessed with a questionnaire
Static balance1 yearfunctional reach test assessed by physically testing the patient with a standardized set of instructions
Blood pressure1 yearChange in blood pressure , physiological parameter
PROMIS (Patient-Reported Outcomes Measurement Information System) Pain Interference and Physical Function1 yearPain and Function measured through PROMIS short forms
Overall activity1 yearoverall activity measured as daily steps, through wristband devices
sleep patterns1 yearTotal sleep time measured in minutes through wristband activity monitor (FitBit) measured over one week
Visual Analog Scale (VAS) for pain measurement1 yearquestionnaire
Medication Consumption1 yearTrack increase or decrease in Medication consumption- assessed through patient interview and patent report
Medication Costs1 yearCalculate monetary savings in Medication Costs- assessed through patient interview and prevailing market cost information
Hospitalization utilizations1 yearCalculate the increase/decrease in hospital facility utilization - assessed with patient interview and health records.
resting heart rate1 yearchange in resting heart rate , physiological parameter

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026